Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco S&P 500 Low Volatility ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Invesco S&P 500 Low Volatility ETF trades at $76.25. Which is the better fit depends on your goals.
| ADPT | SPLV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $77.45 |
52-Week Low | $10.24 | $70.30 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SPLV trades at $76.17, down 0.73% today, maintaining a bullish technical outlook with strong moving average support. The ETF focuses on low-volatility S&P 500 stocks, offering defensive exposure during market uncertainty. Recent news highlights its role in portfolio diversification amid tech sector volatility, with institutional investors showing mixed positioning.
The outlook remains positive for risk-averse investors seeking stable equity exposure. Key risks include potential underperformance during strong bull markets and concentration in defensive sectors. Analyst sentiment is generally favorable for defensive portfolio allocation, though specific financial metrics for the ETF are not publicly detailed like individual stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
